Sol-Gel Technologies announced completion of the pivotal Phase 3 trial for SGT-610, a treatment for Gorlin syndrome, with 102 of 113 patients finishing the study. Top-line results are expected in late November 2026. The company is preparing for potential regulatory submission and U.S. commercialization, aiming to reduce the need for repeated surgeries in patients. Financially, Sol-Gel reported a $5.6 million net loss for Q3 2026 but maintains sufficient cash to fund operations into early 2028.
Sol-Gel's Q3 2026 financial results and corporate updates provide context for readers. For those following the health sector, 82 of 150 priced US health stocks rose while 64 fell as of Nov 12, 2026 20:12 WIB. Notable movers include Takeda Pharmaceutical (TAK) at USD 21.35 with a 2.45% gain and Illumina (ILMN) at USD 208.00 with a 2.32% loss.
Interlink Electronics announced a 3.4% revenue increase to $3.06 million for Q3 2026 and a 9.6% rise to $9.9 million for the first nine months of 2026, driven by higher shipments of force-sensing and gas-sensor products. The company reported a net lo...
ALS Canada, with renewed funding from TD Bank, is advancing its national strategy for ALS genetics to enhance access to genetic information, counselling, and care for Canadians affected by or at risk of ALS. This builds on the 2024 pilot of the first...
The Canadian ALS Society has renewed funding from TD Bank to expand its national genetics strategy for ALS, improving access to genetic information, counseling, and care for those affected or at risk. This initiative builds on a pilot project that cr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
